Hsiri Therapeutics Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$202K
- Investors
-
2
Hsiri Therapeutics General Information
Description
Developer of infectious diseases antibiotics designed to cure mycobacterial diseases. The company's antibiotics utilize the bacteria's own iron capture molecules and couple them to conventional antibacterial compounds which target the antibiotics to the bacteria and can avoid a number of bacterial resistance mechanisms, enabling patients to resist various bacterial diseases.
Contact Information
Website
www.hsiritherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 1400 North Providence Road, Building 1
- Suite 115S
- Media, PA 19063
- United States
+1 (484) 000-0000
Hsiri Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 01-Jan-2016 | $202K | 00000 | Completed | Generating Revenue | |
| 2. Seed Round | 17-Dec-2015 | 0000 | 00000 | Completed | Startup | |
| 1. Seed Round | 11-Jun-2015 | $50K | $50K | Completed | Startup |
Hsiri Therapeutics Patents
Hsiri Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3265130-A4 | Antibacterial sideromycins | Pending | 19-Aug-2014 | 0000000000 | |
| EP-3265130-A1 | Antibacterial sideromycins | Pending | 19-Aug-2014 | 0000000000 | |
| US-11149046-B2 | Antibacterial sideromycins | Active | 19-Aug-2014 | 0000000000 | |
| US-20190153010-A1 | Antibacterial sideromycins | Granted | 19-Aug-2014 | 0000000000 | |
| CA-2957691-A1 | Antibacterial sideromycins | Pending | 19-Aug-2014 | C07F15/025 |
Hsiri Therapeutics Executive Team (5)
Hsiri Therapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carrie Frey | Hsiri Therapeutics | Chief Operating Officer & Board Member | 000 0000 |
| William Claypool MD | Self | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
Hsiri Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Hsiri Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| BioAdvance | Venture Capital | Minority | 000 0000 | 000000 0 |